219 Views

217 - Pain Outcomes of Platelet-rich Plasma and Hyaluronic Acid Treatment in Patients with Osteoarthritis

Thursday, February 27, 2025

5:00 PM - 6:30 PM MST

Presenting Author(s)

IP

Isaiah J. Porter, BA

Medical Student
Idaho College of Osteopathic Medicine
Rapid City, South Dakota, United States

Co-Author(s)

ZP

Zachary Philpot, MHM

Medical Student
Idaho College of Osteopathic Medicine
meridian, Idaho, United States
CC

Conner Charles, BS

Medical Student
Idaho College of Osteopathic Medicine
meridian, Idaho, United States
KS

Kyle Scheer, BS

Medical Student
Idaho College of Osteopathic Medicine
Meridian, Idaho, United States
CR

Chanel Ross, BS

Medical student
University of Arizona college of medicine Tucson
Tucson, Arizona, United States

Objectives: 1) Investigate the efficacy of Platelet-rich Plasma (PRP) and Hyaluronic Acid (HA) on patient outcomes in knee and hip osteoarthritis (OA). 2) Examine the effect of treatments using WOMAC and VAS scores. 3) Compare efficacy of treatment modality based on longitudinal reduction of pain.

Design: Peer-reviewed articles from NIH, Google Scholar, PubMed and UpToDate for research on PRP and its effect on varying patient pain scales.

Results: Patients being treated for hip OA with PRP showed a decrease in WOMAC scores from 29.4 at baseline to 12.0 at 6 months followed by a subsequent increase to 12.3 at 12 months.2 Patients being treated for knee OA with PRP showed a decrease in WOMAC scores from 29.33 at baseline to 16.09 at 6 months followed by a subsequent decrease to 12.85 at 12 months.3 Treatment for both hip and knee OA with PRP demonstrated statistical significance at 6 and 12 months.

Patients being treated for knee OA with PRP showed a decrease in VAS scores from 3.40 at baseline to 3.23 at 6 months followed by an increase to 5.45 at 12 months 5 When comparing different treatment modalities for patients with hip OA, the percent reduction in WOMAC scores 12 weeks after treatment was 23.11% for HA, 30.50% for exercise, 14.67% for placebo, and 56.18% for PRP.2,4–6

Conclusions: Upon reviewing current data, treatment for hip and knee OA with PRP, and hip OA with HA, demonstrated statistical significance at 6 and 12 months utilizing WOMAC and VAS scores respectively. Treatment for knee OA with HA, utilizing VAS scores, was not statistically significant. When compared to baseline, all of the treatment modalities (PRP, HA, and exercise) in regards to WOMAC scores were statistically significant after 12 weeks of treatment. Evaluation of OA treatment modality is warranted to prevent disease progression and increase patient outcomes.